SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma
Clinical Trials
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Investigators have developed a Uveal Melanoma Immunogenomic Score (UMIS) to predict which patients with metastatic uveal melanoma will respond to immunotherapy, according to findings published in Nature Communications.
Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma
This transcript has been edited for clarity.
Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.